Cardiovascular risks of cyclooxygenase inhibition

Pharmacotherapy

Volumn 26, Issue 7 I, 2006, Pages 919-938

  Stacy, Zachary A ^a   Dobesh, Paul P ^b   Trujillo, Toby C ^c  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Cardiovascular risks; COX; Cyclooxygenase; Nonsteroidal anti inflammatory drugs; NSAID

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; LUMIRACOXIB; MELOXICAM; MEMBRANE PHOSPHOLIPID; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PHOSPHOLIPASE; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN G; PROSTAGLANDIN H2; PROSTAGLANDIN SYNTHASE; ROFECOXIB; THROMBOXANE A2; UNINDEXED DRUG; VALDECOXIB;

ACUTE HEART INFARCTION; ANALGESIA; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL ADENOMA; COLORECTAL TUMOR; CORONARY ARTERY BYPASS GRAFT; DIGESTIVE SYSTEM PERFORATION; DRUG SAFETY; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HUMAN; INTRACARDIAC THROMBOSIS; ISCHEMIC HEART DISEASE; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; STROKE; SUDDEN DEATH; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DRUG INTERACTIONS; HUMANS; PROSTAGLANDINS; RISK ASSESSMENT;

EID: 33745698728     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.7.919     Document Type: Article

References (101)

1. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999;340:1888-99.
2. Maxwell SR, Webb DJ. COX-2 selective inhibitors: important lessons learned. Lancet 2005;365:449-51.
3. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
4. Vane JR, Bakhle YS, Botting RM. Cycooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
5. Fitzgerald GA, Austin S, Egan K, Cheng Y, Pratico D. Cyclooxygenase products and atherothrombosis. Ann Med 2000;32(suppl 1):21-6.
6. Belton O, Fitzgerald DJ. Cyclooxygenase isoforms and atherosclerosis. Exp Rev Mol Med 2003;5:1-18.
7. Marnett LJ, Rowlinson SW, Goodwin DC, Kalgutkar AS, Lanzo CA, Arachidonic acid oxygenation by COX-1 and COX-2: mechanisms of catalysis and inhibition. J Biol Chem 1999;274:22903-6.
8. Linton MF, Fazio S. Cyclooxygenase-2 and atherosclerosis. Curr Opin Lipidol 2002;13:497-504.
9. Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001;108:7-13.
10. Chan CC, Boyce S, Brideau C, et al. Rofecoxib (Vioxx, MK-0966; 4-[4′-methylsulfonylphenyl]-3-phenyl-2-[5H]-furanone): a potent and orally active cyclooxygenase and biochemical profiles. J Pharmacol Exp Ther 1999;290:551-60.
11. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003;107:405-9.
12. Segev G, Katz RJ. Selective COX-2 inhibitors and risk of cardiovascular events. Hosp Physician 2004;40;39-46.
13. Konstam MA, Weir MR. Current perspective on the cardiovascular effects of coxibs. Cleve Clin J Med 2002;69(suppl 1):S47-52.
14. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999;289:735-41.
15. Whelton A, White WB, Bello AE, Puma JA, Fort JG, for the SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥ 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002;90:959-63.
16. Palmer R, Weiss R, Zusman RM, Haig A, Flaven S, MacDonald B. Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin-converting enzyme inhibitors. Am J Hypertens 2003;16:135-9.
17. White WB, Kent J, Taylor A, Verburg KM, Lefkowitz JB, Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002;39:929-34.
18. Sowers JR, White WB, Pitt B, et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005;165:161-8.
19. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. II. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
20. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
21. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999;150:341-53.
22. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:413-21.
23. Esser R, Berry C, Du Z, et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol 2005;144:538-50.
24. Tacconelli S, Capone ML, Sciulli MG, Ricciotti E, Patrignani P. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr Med Res Opin 2002;18:503-ll.
25. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J Rheumatol 2000;27:71-5.
26. Reilly PA, Cosh JA, Maddison PJ, Rasker JJ, Silman AJ. Mortality and survival in rheumatoid arthritis: a 25-year prospective study of 100 patients. Ann Rheum Dis 1990;49:363-9.
27. Jacobsson LTH, Knowler WC, Pillemer S, et al. Rheumatoid arthritis and mortality: a longitudinal study in Pima Indians. Arthritis Rheum 1993;36:1045-53.
28. Day R, Morrison B, Luza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000;160:1781-7.
29. Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum 2000;43:978-87.
30. Ehrich EW, Schnitzer TJ, McIlwain H, et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6-week double blind, placebo-controlled pilot study of rofecoxib. J Rheumatol 1999;26:2438-47.
31. Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095-105.
32. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:1921-8.
33. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;117:776-83.
34. Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000;43:370-7.
35. Emery P, Zeidler H, Kvien KT, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: a randomized double-blind comparison. Lancet 1999;354:2106-11.
36. Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol. 2000;95:1681-90.
37. Bombardier C, Laine L, Reicin A, et al, for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
38. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
39. Bresalier RS, Sandler RS, Quan H, et al, for the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
40. Solomon SD, McMurray JJV, Pfeffer MA, et al, for the Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
41. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-84.
42. U.S. Food and Drug Administration. Briefing package for NDA 21-389 etoricoxib. Available from http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005- 4090Bl_31_AA-FDA-Ta b-T.pdf. Accessed October 17, 2005.
43. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003;125:1481-92.
44. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91.
45. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-9.
46. Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40:1109-20.
47. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and nonaspirin nonsteroidal anti- inflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000;11:382-7.
48. Garcia Rodriguez LA, Gonzalez-Perez A. Long term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med 2005;3:17.
49. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
50. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280-8.
51. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002;324:71-86.
52. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
53. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001;85:265-71.
54. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-3.
55. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infraction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-81.
56. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-73.
57. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005;142:481-9.
58. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005;142:157-64.
59. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase-2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163:481-6.
60. Mamdani M, Juurlink DN, Lee DS, et al. Cyclooxygenase-2 inhibitors versus non-selective nonsteroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004;363:1752-6.
61. ClinicalStudyResults.org. Celecoxib PhRMA EQ5-98-02-002 final 0111105.doc. Available from http://www.clinicalstudy results.org/documents/ company-study_76_0.pdf. Accessed October 17, 2005.
62. Gandey A. Naproxen scare overblown, says Washington Post article, February 1, 2005. Available from http://www. theheart.org/viewArticle.do? primaryKey=38666. Accessed October 17, 2005.
63. Benevolenskaya L, Tuzun S, Hagin E, Moore A, Gimona A. Lumiracoxib is effective in relieving symptoms of knee or hip osteoarthritis after 4 weeks of treatment: results from a randomized, placebo-controlled trial [abstr]. Ann Rheum Dis 2003;62(suppl 1):270.
64. Tannenbaum H, Berenbaum F, Reginster JY, et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind study versus placebo and celecoxib. Ann Rheum Dis 2004;63:1419-27.
65. Kivitz AJ, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey C. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther 2004;19:1189-98.
66. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74.
67. Mueller XM, Tinguely F, Tevaeari HT, Revelly JP, Chiolero R, Von Segesser LK. Pain location, distribution, and intensity after cardiac surgery. Chest 2000;118:391-6.
68. Ng A, Smith G, Davidson AC. Analgesic effects of parecoxib following total abdominal hysterectomy. Br J Anaesth 2003;90:746-9.
69. Malan TP Jr, Marsh G, Hakki SI, Grossman E, Traylor L, Hubbard RC. Parecoxib sodium, a parenteral cyclooxygenase 2 selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip arthroplasty. Anesthesiology 2003;98:950-6.
70. Joshi GP, Viscusi ER, Gan TJ, et al. Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor. Anesth Analg 2004;98:336-42.
71. Furberg CD, Psaty BM, FitzGerald GA. Parecoxib, valdecoxib, and cardiovascular risk [editorial]. Circulation 2005;111:249.
72. Konstantopoulos K, Grotta JC, Silis C, Wu KK, Hellums JD. Shear-induced platelet aggregation in normal subjects and stroke patients. Thromb Haemost 1995;74:1329-34.
73. Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 1997;112:676-92.
74. Davies GC, Sobel M, Salzman EW. Elevated plasma fibrinopeptide A and thromboxane B2 levels during cardiopulmonary bypass. Circulation 1980;61:808-14.
75. Zimmerman N, Kienzle P, Webber AA, et al. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001;121:982-4.
76. Zimmerman N, Wenk A, Kim U, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003;108:542-7.
77. Möhnle P, Schwann NM, Vaughn WK, et al. Perturbations in laboratory values after coronary artery bypass graft surgery with cardiopulmonary bypass. J Cardiothorac Vas Anesth 2005;19:19-25.
78. Brochier ML. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. Eur Heart J 1993;14:951-7.
79. Bhara N, McClellan K. Indobufen: an updated review of its use in the management of atherothrombosis. Drugs Aging 2001;18:369-88.
80. Singh G, Mithai A, Triadafilopoulos G. Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient, not the drug class. Presented at the European League Against Rheumatism 2005, Vienna, Austria, June 8-11, 2005.
81. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005;330:1366-73.
82. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005;165:978-84.
83. Fischer LM, Schlienger RG, Matter CM, Jick H, Meier CR. Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Pharmacotherapy 2005;25:503-10.
84. Fischer LM, Schlienger RG, Matter CM, Jick H, Meier CR. Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med 2004;164:2472-6.
85. Rodriguez LAG, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A. Nonsteroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004;109:3000-6.
86. Kimmel SE, Berlin JA, Reily M, et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol 2004;43:985-90.
87. Schlienger RG, Jick H, Meier CR. Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol 2002;54:327-32.
88. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002;162:1105-10.
89. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002;162:1111-15.
90. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002;162:1099-104.
91. Ko D, Berger AK, Radford MJ, Krumholz HM. Nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Am Heart J 2002;143:475-81.
92. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational study. Lancet 2002;359:118-23.
93. Kimmel SE, Berlin JA, Kinman JL, et al. Parental ketorolac and risk of myocardial infarction. Pharmacoepidemiol Drug Safe 2002;11:113-19.
94. Jick SS. The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam. Pharmacotherapy 2000;20:741-4.
95. Sajadieh A, Wendelboe O, Hansen JF, et al. Nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Am J Cardiol 1999;83:1263-5.
96. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
97. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005;45:1295-301.
98. European Medicines Agency Press Office. Public statement: European Medicines Agency announces regulatory action on COX-2 inhibitors. February 17, 2005. Available from www.emea.eu.int/pdfs/human/press/pr/6275705en.pdf. Accessed April 24, 2006.
99. Chan FKL, Hung LCT, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104-10.
100. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term use of nonsteroidal anti-inflammatory drugs: results of a double-blind, multicenter, active- and placebo-controlled study of misoprostol versus lansoprazole. Arch Intern Med 2002;162:169-75.
101. Jacobsen RB, Phillips BB. Reducing clinically significant gastrointestinal toxicity associated with nonsteroidal anti-inflammatory drugs. Ann Pharmacother 2004;38:1469-81.